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Abstract
Opioids have been widely applied in clinics as one of the most potent pain relievers for centuries, but their abuse has
deleterious physiological effects beyond addiction. However, the underlying mechanism by which microglia in response to
opioids remains largely unknown. Here we show that morphine induces the expression of Toll-like receptor 9 (TLR9), a key
mediator of innate immunity and inflammation. Interestingly, TLR9 deficiency significantly inhibited morphine-induced
apoptosis in microglia. Similar results were obtained when endogenous TLR9 expression was suppressed by the TLR9
inhibitor CpGODN. Inhibition of p38 MAPK by its specific inhibitor SB203580 attenuated morphine-induced microglia
apoptosis in wild type microglia. Morphine caused a dramatic decrease in Bcl-2 level but increase in Bax level in wild type
microglia, but not in TLR9 deficient microglia. In addition, morphine treatment failed to induce an increased levels of
phosphorylated p38 MAPK and MAP kinase kinase 3/6 (MKK3/6), the upstream MAPK kinase of p38 MAPK, in either TLR9
deficient or m-opioid receptor (mOR) deficient primary microglia, suggesting an involvement of MAPK and mOR in morphine-
mediated TLR9 signaling. Moreover, morphine-induced TLR9 expression and microglia apoptosis appears to require mOR.
Collectively, these results reveal that opioids prime microglia to undergo apoptosis through TLR9 and mOR as well. Taken
together, our data suggest that inhibition of TLR9 and/or blockage of mOR is capable of preventing opioid-induced brain
damage.
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Introduction
Opioids have been used as potent analgesics for centuries;
however, their abuse has deleterious physiological effects beyond
addiction [1–3]- for example, they can somehow alter the
functions of the immune and nervous systems [1,4,5]. Because
opioid addicts are susceptible to certain infections, opioids such as
morphine, have been suspected to suppress the immune response.
This was supported by findings that various immune-competent
cells express opioid receptors and undergo apoptosis when treated
with opioid alkaloids [1–3,6]. Our previous studies revealed that
chronic morphine exposure, such as occurs in drug abuse,
promotes apoptosis both in vitro and in vivo [1,3,7–9]. In the
central nervous system (CNS), we and others have previously
reported that the importance of opioid-induced apoptosis in
neurons [7,10]. Opioid receptors play critical roles in the processes
of opioid-induced effects. All three opioid receptor types, m, d, and
k have been identified on microglia [4,11].
Microglia are key players of the immune response in the CNS
and represent the resident immune host defense and are
considered the major immune inflammatory cells of the CNS
[12,13]. We and others have shown that morphine treatment-
induced microglia apoptosis could be blocked by naltrexone or
naloxone, specific opioid receptor antagonists, indicating a pivotal
role of opioid receptors in this process [4,14]. Our recent studies
found that a deficiency of Toll-like receptor 2 (TLR2) significantly
inhibits morphine-induced apoptosis in primary neurons [15].
TLRs are well known for recognition of pathogens in the innate
immune system aimed at defending the survival of the host [16–
18]. To date, the TLR family includes a total of 13 receptors that
are responsible for the recognition of highly conserved structural
motifs that are essential for pathogen survival and are conserved
across broad subclasses of microorganism [17,19,20]. Each TLR
family member, with the exception of TLR3, signals through the
MyD88 dependent pathway [17]. TLRs and their functions have
been established in immune cells [17,18]. TLR3, TLR7, and
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onaTLR9 are distinct from other TLRs in that they are not expressed
on the plasma membrane [19,21]. TLR9 was identified as a key
immune receptor in TLRs family that can recognize bacterial
DNA as well as oligodeoxynucleotides (ODN) containing the CpG
motifs responsible for the activating capacity of bacterial DNA
(CpG s-ODN) [21,22]. Activation of TLR9 signaling triggers
activation of proapoptotic signals, and causes cell apoptosis in
various systems [19,21]. Growing evidence suggest that TLRs,
including TLR9, expressed by microglial cells are critical in
identifying and generating innate immune responses against
bacterial and viral pathogens in the CNS [23–25]. Recently, it
has been shown that TLR9, but not TLR2 or TLR4, plays a role
in morphine inhibition of S.pneumoniae-induced NF-kB activity
in the early stage of infection [26]. We have recently shown that
morphine through potent stimulus of TLR9 caused altered host
resistance against Mycobacterium tuberculosis in the lung of
mouse model [19]. However, the role of TLR9 signaling on
opioid-mediated apoptosis remains unknown.
One of three major subfamilies of mitogen-activated protein
kinases (MAPKs) p38 MAPK plays a pro-apoptotic role [4,27,28].
Chronic morphine administration enhances the phosphorylation
of p38 MAPK in dorsal root ganglion neurons [29]. Inhibition of
p38 MAPK by p38 inhibitor SB203580 significantly attenuated
tolerance to morphine analgesia [30]. P38 MAPK seems to
sensitize cells to apoptosis by up-regulating Bax [31,32], a pro-
apoptotic member of the Bcl-2 family [31,32]. The role of TLR9
in p38 MAPK and Bcl-2-mediated microglia apoptosis is not
known yet. The objective of this study was to investigate the
mechanisms by which opioids prime TLR9-mediated microglia
apoptosis. Specifically we determined the involvement of mOR-
mediated pro-apoptotic p38 MAPK and the upstream MAPK
kinase (MKK3/6) of p38 MAPK, and Bcl-2 pathways. Here, we
show that TLR9 is required for morphine-induced microglia
apoptosis through p38 MAPK signaling pathway. Moreover,
morphine promotes primary microglia apoptosis in a m opioid
receptor (mOR) dependent mechanism. Our studies thus provide
an important insight into the mechanism of microglia apoptosis in
response to opioids.
Results
Increased TLR9 expression in wild type microglia
following morphine treatment
Although recent studies have demonstrated that TLR9 is
expressed on microglia, the molecular mechanisms by which
opioids affect microglia function in unknown [4,33]. To define the
mechanisms, we treated primary mouse microglia from wild type
mice with various concentrations of morphine for different time
periods and examined the expression of TLR9 by quantitative real
time RT-PCR and Western blot analysis. TLR9 expression in
mRNA level was significantly increased following morphine
treatment (Fig. 1A). Morphine-induced TLR9 expression was also
detected at the protein level (Fig. 1B). The results demonstrated
that morphine induces TLR9 expression in primary microglia in a
dose and time dependent manner.
TLR9 deficiency prevents morphine-induced microglia
apoptosis
We have recently reported that morphine promotes apoptosis in
micgroglia [4]. To investigate whether TLR9 plays a role in
opioid-induced microglia apoptosis, we treated primary mouse
microglia from TLR9 knockout mice and wild type mice with
Figure 1. Morphine induces TLR9 expression in a dose and time dependent manner in wild type microglia. (A). Morphine induces the
expression of TLR9 in mRNA level in a dose and time dependent. Mouse primary microglial cells were treated with 10 mM morphine for various time
periods or different concentrations of morphine for 12 hr, respectively. The expression of TLR9 was determined by quantitative real time RT-PCR as
described under Materials and Methods. Results represent mean 6 SD of three independent experiments. (B). TLR9 expression in protein levels were
determined by western blot. Cells were treated with 10 mM morphine for various time or various concentrations of morphine for 24 hr, respectively.
Data are representative of three independent experiments.
doi:10.1371/journal.pone.0018190.g001
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TUNEL assay [4,15,19]. As shown in Fig. 2, a significant number
of cells in the wild type microglia following morphine treatment
were undergoing apoptosis, whereas only a few apoptotic cells
were detected in the TLR9 deficient microglia after morphine
treatment. Therefore, our results suggest TLR9 is required in
opioid-mediated apoptosis in primary microglia.
Blockade of TLR9 attenuates morphine-induced
microglia apoptosis
Because TLR9 deficiency inhibited morphine-induced apopto-
sis, we postulated that TLR9 blockade might protect wild type
microglia following morphine treatment. We pretreated wild type
primary microglia cells for 1 hr with the TLR9 inhibitor
CpGODN2088 [34] or vehicle, and then treated with morphine
for 24 hr. Apoptotic cells were analyzed either by TUNEL assay
(Fig. 3A) or by flow cytometric analysis (Fig. 3B). We showed that
co-exposure of wild type microglia to CpGODN2088 and
morphine resulted in a significant decrease in apoptosis compared
to cells treated with morphine alone (Fig. 3), suggesting that this
approach may be useful clinically.
Inhibition of p38 MAPK diminishes morphine-induced
microglia apoptosis
Opioids promote macrophage apoptosis through p38 MAPK
phosphorylation [35]. To determine the role of p38 MAPK on TLR9-
mediated microglia apoptosis induced by morphine exposure, we
pretreated wild type and TLR9 deficient primary microglial cells with
the specific p38 MAPK inhibitor SB 203580 [4] and then treated the
cells in the presence or absence of morphine. We determined cell
apoptosisbyeitherTUNELassay(Fig. 4A)orflowcytometry (Fig. 4B).
As shown in Fig. 4, inhibition of p38 MAPK by SB203580
significantly attenuated morphine-induced apoptosis in wild type
primary microglial cells. SB203580 did not alter the effects of
morphine on TLR9 deficient microglial cells. SB203580 alone did not
induce apoptosis in either wild type or TLR9 deficient microglial cells.
Inhibition of p38 MAPK attenuates morphine-induced
alteration of Bcl-2 and Bax expression
It has been reported that p38 MAPK modulates Bcl-2/Bax-
mediated apoptosis in neuroblastoma cells [32,36]. Our previous
studies have reported that treatment of morphine with R37Ra
protein significantly decreased the level of Bcl-2 and increased the
level of Bax in the lung from wild type mice [19]. To examine
whether p38 MAPK modulates Bcl-2 signaling following morphine
treatmentinTLR9-mediatedsignaling,weexaminedtheexpression
of anti-apoptotic Bcl-2 and pro-apoptotic Bax by Western blot.
Primary wild type microglia and TLR9 deficient microglial cells
were treated with SB203580 for 1 hr and then treated with or
without morphine for 24 hr. Morphine treatment significantly
enhanced the expression of Bax but decreased Bcl-2 expression in
wild type microglial cells (Fig. 5). In contrast, morphine did not alter
the levels of Bcl-2 and Bax in the microglia from TLR9 knockout
mice, suggesting that Bcl-2 family participates in TLR9-mediated
microglia signaling following morphine treatment. Intriguingly,
inhibition of p38 MAPK by SB203580 significantly diminished
morphine-induced changes of Bcl-2 and Bax compared with the
morphine treatment alone in wild type microglial cells, but not in
TLR9 deficient microglial cells. SB203580 alone did not alter the
level of Bax (Fig. 5). Thus, our data suggest that TLR9 plays a
critical role in p38 MAPK-mediated Bcl-2 signaling in microglial
cells following morphine treatment.
Effect of TLR9 and mOR on the levels of phosphor-p38
MAPK and phosphor-MKK3/6 following morphine
treatment
Since inhibition of p38 MAPK could effectively block the
morphine-induced apoptosis in wild type microglial cells (Fig. 4),
its consequence on the level of phosphorylation of p38 MAPK was
next determined in wild type and TLR9 deficient microglial cells
with 10 mM morphine treatment for 24 hr. As shown in Fig. 6A,
morphine significantly enhanced the level of phospho-p38 MAPK
in wild type microglial cells. The increase of phosphor-p38 in wild
type microglial cells was attenuated markedly in TLR9 deficient
primary microglia. We have shown that morphine induces
microglia apoptosis through opioid-receptors [4]. To examine
the role of mOR, a key opioid receptor of opioids’ actions, we
determined the level of phospho-p38 MAPK in mOR deficient
microglial cells following morphine treatment. We found that a
deficiency of mOR in primary microglia strongly suppressed the
level of P38 phosphorylation compared with wild type primary
microglia following morphine treatment (Fig. 6A).
Next, we examine the of phosphorylation level of MKK3/6, the
upstream MAPK kinase of p38 MAPK, in microglial cells with
Figure 2. A deficiency of TLR9 is resistant to morphine-induced microglia apoptosis. Wild type (WT) and TLR9 deficient (TLR9 KO)
microglia were treated with or without 10 mM morphine for 24 hr. Apoptotic cells (dark brown color cells) were determined by TUNEL assay.
Photographs of representative TUNEL-stained cells are shown at the top. Magnification 2006. The bar graph shows the percentage of apoptotic cells.
Results represent mean 6 SD from three independent experiments. * p,0.01 compared with indicated groups.
doi:10.1371/journal.pone.0018190.g002
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resulted in a dramatic increase of MKK3/6 phosphorylation level
in wild type primary microglia, but not in TLR9 or mOR deficient
primary microglia (Fig. 6B). Taken together, these results suggest
that p38 MAPK and MKK3/6 are involved in morphine-
mediated microglia apoptosis through TLR9 and/or mOR.
Morphine induces microglia apoptosis through mOR
It has been established that several opioid receptor isoforms,
including mOR, are expressed on microglia [11]. To test whether
morphine-induced TLR9 is through mOR, we treated primary
microglia from mOR knockout mice and from wild type mice with
morphine at 10 mM and examined the expression of TLR9 by
quantitative real time RT-PCR and immunohistochemistry. The
expression of TLR9 was significantly induced by morphine in wild
type microglia (data not shown), consistent with the findings of our
results in Figure 1. Importantly, morphine could not alter the
expression of TLR9 in mOR knockout microglia both in mRNA
level (Fig. 7A) and protein level (data not shown). Taken together,
our results demonstrated that morphine treatment significantly
increases TLR9 expression through mOR.
Figure 3. Inhibtion of TLR9 by CpGODN2088 blocked morphine-induced apoptosis in wild type microglia. WT microglial cells were
exposed to 5 mM CpGODN2088 (ODN) for 1 hr and then treated with morphine at 10 mM for 24 hr. (A). Apoptotic cells were determined by TUNEL
assay as in Fig. 2. Representative light microscopic images showed TUNEL-positive microglia (red arrow head) Results represent mean 6 SD of three
independent experiments. * p,0.01 compared with indicated groups. (B). Cell apoptosis was also assayed by flow cytometry after staining with
annexin V and propidium iodide as described under ‘‘Materials and Methods’’. These results are representative of three independent experiments.
doi:10.1371/journal.pone.0018190.g003
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in morphine-induced microglia apoptosis. Primary wild type
microglial cells were exposed to morphine at 10 mM in the presence
or absence of the opioid-receptor antagonist naloxone [4,9,37].
Apoptotic cells were examined either by TUNEL assay (Fig. 7B) or
by flow cytometric analysis (Fig. 7C). We observed that pretreat-
ment with naloxone dramatically blocked morphine-induced
microglia apoptosis (Figs. 7B and 7C). Treatment of microglia with
naloxone alone did not alter the percentage of apoptosis (data not
shown). We next tested with a specific mOR agonist [D-Ala2, N-
MePhe4, Gly-ol]-enkephalin (DAMGO). DAMGO significantly
induced microglia apoptosis but no significant difference was
observed when compared with the morphine treatment group
(Figs. 7B and 7C). Morphine could not cause apoptosis in mOR
deficient microglia (data not shown). Therefore, morphine-induced
microglia apoptosis appears to require mOR.
Discussion
The data presented herein revealed for the first time, to our best
knowledge, a key role for microglia TLR9 in the induction of
morphine-mediated apoptosis. Our studies demonstrate that
Figure 4. Inhibition of p38 MAPK by SB203580 attenuates morphine-induced microglia apoptosis. WT microglial cells and TLR9
deficient microglial cells were pretreated with 10 mM SB203580 (SB) for 1 hr and then exposed to morphine at 10 mM for 24 hr. Apoptotic cells were
determined as in Fig. 3. (A). Representative light microscopic images showed TUNEL-positive microglia (red arrow head). Magnification 2006. Results
represent mean 6 SD from three independent experiments. * p,0.01 compared with indicated groups. (B). Apoptotic cells were analyzed by flow
cytometry. Three experiments were performed with similar results.
doi:10.1371/journal.pone.0018190.g004
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microglia apoptosis. It is widely accepted that TLR9 signaling
mainly activates inflammatory responses, including proinflamma-
tory cytokines [18,21,22,38]. Many studies focused attention on
TLR9-mediated apoptosis in immune system [18,21]. Recent
studies have shown that apoptosis via TLR9 on immune cells may
play a role in the pathogenesis of various autoimmune diseases
[39]. In this study, we identify that deficiency of TLR9 activity in
primary microglia blocked morphine-induced microglial apopto-
sis. Morphine concentration we used in this study is physiologically
relevant and these levels can be achieved in the brains of patients
given opioids [4,14,40,41]. Our studies revealed that TLR9
signaling is activated by opioids in microglia without the presence
of immune cells. We discovered that the absence of TLR9 blocked
microglia apoptosis induced by morphine treatment (Fig. 2).
Importantly, these features in TLR9 deficient microglia were
replicated in wild type microglia through the administration of the
TLR9 inhibitor ODN2088 (Fig. 3). Thus, our results demonstrat-
ed that TLR9 is required in morphine-induced apoptosis in
microglia. This provides a possible target for control of morphine
caused neurotoxicity and brain damage.
MAPKs are a family of serine/threonine kinases that perform
important functions as mediators of cellular responses to various
extracellular stimuli, including cell survival and apoptosis [27,28].
MAPKs consist of three major subfamilies in mammalian cells
[27,28], such as p38 MAPK. The activation of p38 kinase activity
generally promotes apoptosis [27]. We showed that inhibition of
p38 MAPK attenuated morphine-induced apoptosis in microglia
(Fig. 4). It has been shown that morphine treatment increases the
phosphorylation of p38 MAPK in neurons [29]. We found in this
study that morphine induces microglia p38 MAPK activation in
wild type microglia but not in either TLR9 deficient microglia or
mOR deficient microglia (Fig. 6). In addition, we identified that
MKK3/6 was also activated in wild type microglia, but not in
TLR9 deficient microglia or mOR deficient microglia, following
morphine treatment. The results suggest that morphine’s pro-
apoptotic effects observed in microglia are due part to the
activated MKK3/6-p38 MAPK signaling.
Recently, it has been shown that p38 is necessary for Bcl-2-
induced inhibition of apoptosis in fibroblasts [42]. Previous studies
observed that morphine induces lymphocyte apoptosis through
mechanisms associated with a decrease in anti-apoptotic protein
Bcl-2 expression and an enhancement in that of pro-apoptotic
protein Bax [43,44]. The role of Bcl-2 and Bax in p38 MAPK-
mediated microglia apoptosis was investigated in our studies. We
found that morphine significantly decreased the levels of Bcl-2 and
increased the levels of Bax in the microglia from wild type mice.
Interestingly, inhibition of p38 MAPK attenuated morphine-
induced the alterations of Bcl-2 and Bax expression (Fig. 5).
However, morphine did not alter the levels of Bcl-2 and Bax in the
microglia from TLR9 knockout mice. Taken together, our studies
demonstrate that Bcl-2 and Bax participate in TLR9-mediated
p38 MAPK signaling in morphine-induced apoptosis in microglia.
Previous in vitro studies have demonstrated that morphine and
DAMGO, a specific m-opioid receptor agonist, induce apoptosis in
lymphocytes [44]. Our results showed that morphine induces
microglia apoptosis through a mOR dependent mechanism (Fig. 7).
To discriminate between the eventual effect of morphine on TLR9
and mOR, we have made a novel observation that morphine could
not induce TLR9 expression in primary mOR deficient microglia
in both mRNA and protein levels. Therefore, the regulation of
TLR9 by morphine described here is mOR dependent. However,
it is unclear how up-regulation of TLR9 leads to apoptosis induced
by either morphine or DAMGO. The mechanisms by which
morphine as well as DAMGO leads the up-regulation of TLR9 to
microglia apoptosis will be investigated in future studies. It has
been recently reported that opioids induce glial action not though
classical opioid receptors, but rather through non-stereoselective
activation of TLR4 [45]. However, the role of non- stereoselective
TLR4-mediated signaling remains under investigation [45]. To
our best knowledge, we provided the fist evidence that morphine
induces TLR9 expression through a classical mOR dependent
mechanism. Further investigations should be performed to
understand the mechanisms on TLR9 regulation by morphine
via mOR.
Materials and Methods
Experimental animals
TLR9 knockout (TLR9 KO) mice were kindly provided by Dr.
Shizuo Akira, Osaka University, Osaka, Japan via Dr. Dennis
Klinman, National Cancer Institute, Frederick, MD [19]. Mu-
opioid receptor KO mice were kindly provided by Dr. Srinivasa
Raja, Johns Hopkins University School of Medicine, Baltimore,
MD [8]. KO mice and wild type mice were maintained in the
same room in the Division of Laboratory Animal Resources at
East Tennessee State University (ETSU), a facility accredited by
the Association for the Assessment and Accreditation of Labora-
tory Animal Care International (AAALAC). All aspects of the
animal care and experimental protocols were approved by the
ETSU Committee on Animal Care.
Reagents
Morphine sulfate and naloxone were obtained from Sigma-
Aldrich (St. Louis, MO). Antibodies, including total and phospho-
p38 and MKK3/6, were purchased from Cell Signal Technology
(Beverly, MA). TLR9 antibody was purchased from IMGENEX
Figure 5. Blockade of p38 MAPK by SB203580 inhibits
morphine-induced changes in Bcl-2 and Bax expression levels.
WT microglia were exposed to SB203580 (SB) at 10 mM and then treated
with morphine at 10 mM for 24 hr. The expression of Bax and Bcl-2 was
examined by Western blot analysis. Representative results of the levels
of Bcl-2 and Bax are shown of each pane. Mean values were derived
from three independent experiments. * p,0.01 compared with
indicated groups.
doi:10.1371/journal.pone.0018190.g005
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purchased from Santa Cruz Biotechnology (Santa Cruz, CA). P38
inhibitor SB203580 was obtained from Tocris Bioscience (Bristol,
UK). TLR9 inhibitor ODN2088 was obtained from InvivoGen
(San Diego, CA).
Primary microglial cells culture
Mouse primary microglial cells were isolated from mixed glial
cultures, as described in our previous studies [4,46]. Briefly,
primary mixed glial cultures were prepared from postnatal day 1–
2 mice. Primary microglia were co-cultured with astrocytes in
Figure 6. Effect of morphine on p38 MAPK and MEKK3/6 activation. WT, TLR9 KO, and mOR KO microglial cells were treated with morphine
at 5 and 10 mM for 24 hr. (A) Total and phosphorylated p38 MAPK (p-p38 MAPK) levels were determined by Western blot. Mean values were derived
from three independent experiments. * p,0.01 compared with indicated groups. (B) Total and phosphorylated MKK3/6 (p-MKK3/6) levels were
examined by Western blot. Mean values were derived from three independent experiments. * p,0.01 compared with indicated groups.
doi:10.1371/journal.pone.0018190.g006
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2 culture flasks in DMEM (Gibco
BRL, Gaithersburg, MD) supplemented with 10% heat-inactivat-
ed fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville,
GA) and 1% Penicillin/Streptomycin. On days 10–14, microglial
cells were harvested by shaking the cultures (180 rpm) and
collecting the floating cells. These cells were seeded into plastic
tissue culture flasks. After incubation at 37uC for 1 h, non-
adherent cells were removed by replacing culture medium. The
cells were grown in DMEM with 10% FBS and maintained at
37uC and 5% CO2. The purity of microglia was verified .95% by
ricinus communis agglutinin-1 (RCA-1, a microglia marker)
immunostaining.
Figure 7. Morphine induces microglia apoptosis in a mOR dependent manner. (A) Morphine could not induce the expression of TLR9 in mOR
KO microglia. mOR deficient microglia cells were treated morphine at 10 mM for 12 hr and the expression of TLR9 in mRNA levels determined by
quantitative real time RT-PCR as in Fig. 1A. Wild type microglial cells were treated with 10 mM morphine with or without 20 mM naloxone
pretreatment. Another group of cells were treated with 10 mM DAMGO alone for 24 hr. Apoptotic cells were examined as in Fig. 3. (B). Representative
light microscopic images showed TUNEL-positive microglia (red arrow head). Magnification 2006. Results represent mean 6 SD from three
independent experiments. * p,0.01 compared with indicated groups. (C). Apoptotic cells were analyzed by flow cytometry. These results are
representative of three independent experiments.
doi:10.1371/journal.pone.0018190.g007
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Western blot was performed as described previously in our
published work [3,46,47]. Briefly, the cellular proteins were
separated by SDS–polyacrylamide gel electrophoresis and trans-
ferred onto Hybond ECL membranes (Amersham Pharmacia,
Piscataway, NJ). The membrane was then incubated at room
temperature in a blocking solution composed of 5% skim milk
powder dissolved in 16TBS (10 mM Tris, pH 8.0, and 140 mM
NaCl) for 1 h. The membrane was then incubated with the
blocking solution containing the first antibody overnight at 4uC.
After washing three times with TBS for 5 min, the blot was then
incubated with a second antibody. The blot was again washed
three times with TBS before being exposed to the SuperSignal
West Dura Extented Duration substrate (Pierce Biotechnology,
Rockford, IL). Band intensity was quantified by densitometric
analyses using a densitometer.
Quantification of apoptosis by TUNEL assay
The experimental cells were treated with different concentra-
tions of morphine in the presence or absence of SB203580 for 24 h
or ODN2088 for 1 h. Apoptotic cells were determined by terminal
deoxynucleotidyl transferase biotin-d UTP nick end labeling
(TUNEL) assay using a situ cell death detection kit (Roche
Diagnostic, Indianpolis, IN) according to the manufacturer’s
instruction as described in our previous studies [19,37,47]. The
percentage of apoptotic cells was calculated by counting
approximately 500 cells.
Flow cytometry
Apoptotic cells were examined by flow cytometry as described
previously [1,37,48]. Briefly, cells (1610
6) were washed twice with
cold PBS and then suspended cells in 200 mL of 1X binding buffer
and 5 mL of fluorescein isothiocyanate (FITC)-labeled Annexin V
(R&D Systems, Minneapolis, MN) for 20 minutes in the dark, and
thereafter 300 mL of 1X binding buffer and 5 mL of propidium
iodide (Sigma, St. Louis, MO) were added to each sample. After
incubation at RT (25uC) for 10 min in the dark, the cells were
analyzed for apoptosis on a FACScan flow cytometer with
CellQuest software (Becton Dickinson). All data are representative
of three independent experiments.
Real-time quantitative RT-PCR
Total RNA was isolated from lungs by the VERSA GENE
TM
RNA Tissue Kit (Gentra SYSTEMS; Minnesota) and the real-
time RT-PCR detection technique was performed as described in
our previous publications [15,19]. Briefly, first-strand cDNA was
synthesized from 1 mg of total RNA using a Reaction Ready
TM
first strand cDNA synthesis kit (SABiosciences, Frederick, MD).
cDNA was subjected to real-time quantitative PCR using Bio-Rad
iCycler iQ Multicolor Real-Time PCR Detection System (Bio-
Rad Life Science Research, Hercules, CA). TLR9 primer pairs
were used: CCCTGGTGTGGAACATCAT (forward) and
GTTGGACAGGTGGACGAAGT (reverse). PCR assay was
performed in triplicate. The reaction conditions were: 50uC for
2 min, 95uC for 8 min 30 s, followed by 27 cycles of 95uC for 15 s,
60uC for 60 s, and 72uC for 30 s.
Statistical analysis
Results were expressed as mean 6 SD. Statistical significance
was assessed by one-way analysis of variance (ANOVA) and the
student’s test. Prism 5.0 (GraphPad Software, San Diego, CA) was
used for all calculations. A value of p,0.05 was considered
statistically significant.
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